Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCarlo-Stella, Carmelo
dc.contributor.authorZINZANI, PIER LUIGI
dc.contributor.authorSureda, Anna
dc.contributor.authorAraújo, Luis
dc.contributor.authorCasasnovas, René-Olivier
dc.contributor.authorCecilia del Carmen, Carpio Segura
dc.date.accessioned2023-05-12T11:26:47Z
dc.date.available2023-05-12T11:26:47Z
dc.date.issued2023-02
dc.identifier.citationCarlo-Stella C, Zinzani PL, Sureda A, Araújo L, Casasnovas O, Carpio C, et al. A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma. Hematol Oncol. 2023 Feb;41(1):108–19.
dc.identifier.issn1099-1069
dc.identifier.urihttps://hdl.handle.net/11351/9525
dc.descriptionLimfoma difús de cèl·lules B grans; Limfoma no Hodgkin
dc.description.sponsorshipThis study was sponsored by Sanofi.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesHematological Oncology;41(1)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectAnticossos monoclonals - Ús terapèutic
dc.subjectHodgkin, Malaltia de - Tractament
dc.subjectLimfomes - Tractament
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.mesh/therapeutic use
dc.subject.meshLymphoma, T-Cell, Peripheral
dc.subject.meshHodgkin Disease
dc.titleA phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/hon.3089
dc.subject.decsanticuerpos monoclonales humanizados
dc.subject.decs/uso terapéutico
dc.subject.decslinfoma de células T periféricas
dc.subject.decsenfermedad de Hodgkin
dc.relation.publishversionhttps://doi.org/10.1002/hon.3089
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Carlo-Stella C] Department of Biomedical Sciences, Humanitas University and Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milano, Italy. [Zinzani PL] IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy. [Sureda A] Institut Català D'Oncologia ‐ Hospital Duran i Reynals, IDIBELL, Universitat de Barcelona, Barcelona, Spain. [Araújo L] Universitário de Coimbra, Coimbra, Portugal. [Casasnovas O] Hématologie Clinique, CHU Dijon Bourgogne, Dijon, France. [Carpio C] Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid36251503
dc.identifier.wos000876789000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple